Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and PK of Esketamine in Healthy Subjects
NCT02343289Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2015
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of esketamine in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at Day 3, Time to Reach Maximum Plasma Concentration at Day 3 and 7 more. Started Jan 2015; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02343289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02343289.